Immunotherapy
Immunotherapy is a groundbreaking approach to cancer treatment that leverages the body's immune system to identify and eliminate malignant cells while sparing healthy tissues. This method involves enhancing or stimulating the immune system's natural capabilities to recognize and destroy cancer cells, marking a significant advancement in oncology.[1.1]
The historical development of immunotherapy can be traced from early observations of immune responses against tumors to its eventual integration into modern oncology treatments. As advancements in microscopy and pathology emerged in the early 20th century, researchers began to identify immune cells infiltrating tumors, which raised questions about their function in cancer biology.[2.1] The idea of using immunotherapy in cancer gained renewed prominence in 1957 when Thomas and Burnet proposed the theory of cancer immunosurveillance, highlighting the immune system's role in recognizing and eliminating cancer cells.[4.1] This foundational concept paved the way for the incorporation of various immune-based treatments, including IL-2 antibody therapies, checkpoint inhibitors, and monoclonal antibodies, into clinical practice, often tailored to individual tumor biomarkers and genetic profiles.[2.1]
Immunotherapy is often perceived as a relatively recent advance; however, its origins can be traced back to antiquity, where early attempts to modulate the immune system for cancer treatment were made under different names.[5.1] Significant progress in the field was marked by the discovery of T cells in 1967, which revealed their crucial role in immunity and catalyzed research into modern cancer immunotherapy.[6.1] Clinical trials have demonstrated that biological response modifier (BRM) therapy, also known as biologic therapy, biotherapy, or immunotherapy, is effective for many types of cancer, with some biologic agents being naturally occurring in the body and others developed in the laboratory.[7.1]
Recent advancements have further refined immunotherapy, particularly through the characterization of tumor-infiltrating immune cells and their therapeutic implications. This ongoing research aims to enhance the effectiveness of immunotherapy, although the response rates can vary significantly among different cancer types.[8.1] Overall, immunotherapy represents a monumental breakthrough in cancer treatment, fundamentally altering the landscape of oncology and offering new hope for patients.[3.1]
Immunotherapy operates through various mechanisms that enhance the immune system's ability to recognize and eliminate cancer cells. One of the foundational concepts in this field is cancer immunoediting, which describes the dynamic interaction between tumor cells and the immune system within the tumor microenvironment (TME). This process consists of three distinct phases: elimination, equilibrium, and escape, wherein the immune system can both protect against cancer development and inadvertently shape tumor evolution.[45.1]
Recent advancements in immunotherapy have focused on leveraging immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, work by enhancing the immune response against tumors, thereby providing significant clinical benefits in various cancers, including melanoma and non-small-cell lung cancer.[15.1] These therapies aim to overcome the inhibitory signals that tumors use to evade immune detection, allowing T cells to become re-activated and effectively eliminate cancer cells through the release of cytokines and cytolytic mechanisms.[44.1]
Recent advances in cancer immunotherapy, particularly through the use of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly enhanced the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, improve the body's immune response against tumors, providing substantial benefits in treating cancers like melanoma, non-small-cell lung cancer, and lymphoma.[15.1] Ongoing research is investigating combination therapies that integrate ICIs with CAR T-cell therapy, alongside improved CAR T-cell engineering and strategies to modulate the tumor microenvironment, which aim to enhance immune cell infiltration and function within tumors.[15.1] Additionally, thematic analysis has identified immunosenescence and its implications for immunotherapy as prominent research hotspots, indicating a growing focus on understanding how the aging immune system affects treatment efficacy.[14.1]
The interplay between the immune system and cancer is further elucidated by the concept of cancer immunoediting, which emphasizes the necessity of understanding local immune responses within the TME to identify mechanisms of immunotherapy resistance and develop strategies to overcome these challenges.[44.1] As research continues to evolve, the integration of these insights into clinical practice is expected to solidify immunotherapy's role as a cornerstone of cancer treatment.[13.1]
The development of immunotherapy has been marked by several significant milestones that have shaped its evolution as a treatment modality for cancer. The journey began in 1890 with the discovery of serum therapy for infectious diseases, which laid the groundwork for future immunotherapeutic approaches.[47.1] In the following decades, particularly during the 1930s and 1940s, researchers explored the use of bacteria to treat tumors, achieving intermittent success by inducing necrosis in cancerous tissues.[48.1]
The concept of immunotherapy gained further traction in 1957 when the theory of cancer immunosurveillance was proposed by Thomas and Burnet, suggesting that the immune system plays a critical role in identifying and eliminating cancer cells.[4.1] This theoretical framework set the stage for subsequent advancements in the field.
The development of immunotherapy has a rich history, with significant milestones marking its evolution. Tumor necrosis factor (TNF) was identified as a cancer immunotherapy in the 1970s, representing a major advancement in the field.[48.1] In recent years, particularly over the last decade, the clinical landscape has transformed dramatically with the emergence of active immunotherapies. Notably, immune checkpoint inhibitors (ICIs), such as PD-1 and PD-L1, have been integrated into standard-of-care treatments for various cancer types.[49.1] This rapid development underscores the growing importance of immunotherapy in oncology.
Recent years have witnessed an explosion in the clinical development of immunotherapies, with a focus on understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.[3.1] The integration of these therapies into oncology has been facilitated by advancements in laboratory techniques and clinical applications, allowing for a more tailored approach to cancer treatment based on individual tumor profiles.[53.1]
Recent advancements in immunotherapy have led to the emergence of innovative treatment approaches that significantly enhance cancer management. Cancer immunotherapy, which engages the immune system to recognize and eliminate cancer cells, has become a distinct pillar of cancer therapy. Among the most promising modalities are therapeutic vaccines, immune checkpoint blockade, bispecific T-cell engagers (BiTEs), and adoptive cell therapies, all of which share a common mechanism of action aimed at stimulating the immune response against tumors.[95.1]
The landscape of immunotherapy is continually evolving, with a notable shift from traditional therapies to newer modalities. Recent analyses indicate that while the number of new immuno-oncology (IO) clinical trials has decreased for the first time since 2018, there is a record number of IO targets being investigated, with 195 targets currently in clinical trials.[102.1] This shift reflects an improved understanding of cancer pathogenesis, which has facilitated the development of targeted agents alongside immunotherapy.[101.1]
Personalized medicine is also playing a crucial role in the evolution of immunotherapy. By harnessing the specific characteristics of individual tumors, personalized therapies aim to achieve better clinical outcomes compared to traditional treatment approaches. For instance, adoptive cell therapy and neoantigen vaccines exemplify how the immune system can be tailored to enhance therapeutic efficacy.[96.1] Clinical trials have demonstrated that patients with DNA repair gene mutations, which result in higher tumor mutational burden (TMB), exhibit significantly better recurrence-free survival rates.[98.1] Furthermore, recent studies involving personalized neoantigen vaccines have shown promising results, with objective response rates of 59%, 39%, and 27% in melanoma, non-small cell lung cancer (NSCLC), and bladder cancer, respectively.[98.1]
Immunotherapy has also shown remarkable success in treating advanced cancers such as lung cancer, melanoma, and advanced bladder and kidney cancer, with the list of treatable cancers continuing to expand as more drugs undergo clinical trials.[94.1] Unlike traditional chemotherapies that directly target cancer cells, immunotherapy enhances the innate immune response, providing a more targeted and potentially longer-lasting effect with fewer side effects.[99.1] This innovative approach is increasingly being integrated into first-line treatments for various cancers, demonstrating significant benefits for patients who have not responded well to conventional therapies.[100.1]
The field of immunotherapy faces several significant challenges that must be addressed to enhance its efficacy and accessibility. One major hurdle is the limitations of current animal models, which often fail to accurately predict the efficacy of immunotherapy strategies in humans. This discrepancy complicates the transition from laboratory studies to clinical trials, as researchers struggle to establish reliable preclinical findings that can be translated into effective treatments for patients.[116.1] Additionally, the complexity of cancer, characterized by tumor heterogeneity and immune escape mechanisms, presents another significant challenge in developing effective immunotherapeutic agents.[115.1]
Traditional clinical trial designs have faced significant limitations due to the rapid increase in knowledge and pharmaceutical development, particularly the pharmacological differences in toxicity profiles and effectiveness patterns between immunotherapy and chemotherapy. This evolution in trial designs is necessary to address these emerging challenges.[117.1] Among the key hurdles identified in the transition from laboratory studies to clinical trials are the limitations of current animal models to predict the efficacy of cancer immunotherapy strategies in humans, prolonged approval times for initiating clinical trials, and the complexity of cancer, including tumor heterogeneity and immune escape.[115.1] Additionally, the lack of definitive biomarkers for assessing the clinical efficacy of cancer immunotherapies complicates the evaluation of treatment responses and the identification of optimal therapeutic combinations.[115.1] Addressing these challenges will require collaborative efforts from both basic researchers and clinicians, focusing resources to enhance the understanding of the complex interactions between cancer and the immune system.[116.1]
Patient experiences and feedback are crucial for informing future research and development in the field of immunotherapy, particularly regarding immune checkpoint inhibitors (ICIs). A systematic review has indicated that while an increasing number of patients are considering or undergoing immunotherapy, there remains a limited understanding of their perspectives on this treatment.[126.1] The review identified three analytical themes: decision-making related to treatment, the experiences and impacts of receiving ICIs, and the appraisal of immune-related adverse events (irAEs).[124.1] These findings reveal significant unmet information, psychological, and practical support needs among patients, emphasizing the necessity of understanding their treatment experiences to ensure safe and effective person-centered care.[125.1] Furthermore, it has been observed that existing cancer decision-making pathways often prioritize clinical management over patients' preferences and priorities, highlighting a notable gap in the literature concerning the immunotherapy decision-making process across various tumor sites and stages of disease.[127.1] This underscores the urgent need for more inclusive frameworks that take patient priorities into account in the development of treatment protocols.
As the field continues to evolve, addressing these challenges will require collaborative efforts between basic researchers and clinicians, focusing on the complex interactions between cancer and the immune system. By overcoming these obstacles, the potential for improved treatment options and outcomes for patients with cancer can be realized.[116.1]
Monoclonal antibodies represent a crucial category of immunotherapy utilized in cancer treatment. These targeted antibodies are designed to disrupt the activity of cancer cells and alert the immune system to their presence.[134.1] Immunotherapy enhances the immune system's ability to combat cancer, and various types of immunotherapy, including monoclonal antibodies, have been approved for treating numerous cancer types.[135.1] By facilitating a more effective immune response, these therapies contribute significantly to the overall strategy of cancer management.
Immunotherapy represents a significant advancement in cancer treatment, as it encompasses a variety of approaches that harness the body's own immune system to combat malignancies.[136.1] This umbrella term includes the use of drugs, biological agents such as monoclonal antibodies and cytokines, as well as vitamins, minerals, transplantation, and immunizations.[137.1] The primary goal of immunotherapy is to modulate immune responses, either by upregulating or downregulating them, to achieve therapeutic effects in various immunologically mediated disorders, including cancer.[137.1] By employing these diverse modalities, immunotherapy aims to improve the quality of life and life expectancy for patients suffering from a range of conditions, including malignancies and autoimmune diseases.[137.1]
Monoclonal antibodies are a significant component of cancer immunotherapy, classified under targeted antibodies, which can disrupt cancer cell activity and alert the immune system to the presence of cancer cells.[134.1] This type of immunotherapy enhances the body's natural defenses against cancer, contributing to improved treatment outcomes. Various forms of immunotherapy, including cancer vaccines and oncolytic virus therapy, further complement the role of monoclonal antibodies by educating the immune system about cancer cells and utilizing viruses that specifically target and destroy cancer cells, respectively.[134.1] Overall, the integration of monoclonal antibodies into cancer treatment strategies represents a powerful advancement in the fight against cancer, aiming to improve patient survival rates and quality of life.
CAR T-cell therapy is a groundbreaking form of cancer immunotherapy that utilizes genetically engineered T cells to target and eliminate cancer cells. This approach has shown significant promise, particularly in the treatment of hematological malignancies. As of July 31, 2023, the U.S. Food and Drug Administration (FDA) has approved six distinct CAR T-cell therapies, which are designed to enhance the body’s immune response against various types of blood cancers.[147.1]
Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer immunotherapy, particularly for hematological malignancies.[134.1] This innovative approach involves the use of genetically engineered T cells that can recognize tumor antigens, enhancing the immune response against cancer.[135.1] The importance of the interaction between cancer cells and immune cells has been increasingly acknowledged, highlighting the role of these engineered T cells in effective cancer treatment.[135.1] As a result, CAR T-cell therapies have emerged as a promising option in the landscape of cancer immunotherapy, contributing to improved treatment outcomes for patients with specific blood cancers.[134.1]
Immunotherapy has emerged as an advanced treatment approach for a range of cancers, including both hematological malignancies and solid tumors. This strategy harnesses the patient's immune system to combat cancer, offering a pathway to more targeted and efficient treatments. Compared to traditional chemotherapy, immunotherapy is associated with fewer side effects, making it a promising therapeutic option.[149.1] Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.[163.1]
Immunotherapy has shown significant promise in improving survival rates and progression-free survival among cancer patients, particularly those who have not responded to first-line therapies. Studies indicate that the use of immunotherapy, whether as a standalone treatment or in conjunction with conventional cancer therapies, can enhance overall survival and progression-free survival rates, especially in patients experiencing disease recurrence after initial treatments.[178.1]
The efficacy of immunotherapy, particularly immune checkpoint inhibitors (ICIs), varies significantly across different cancer types. For example, the objective response rates for single-agent PD-1 inhibitors range from almost nonexistent in pancreatic cancer and microsatellite-stable colonic adenocarcinoma to an average of 15%–30% in most other tumor types. In contrast, cancers such as melanoma, Hodgkin lymphoma, squamous-cell carcinoma of the skin, and Merkel cell carcinoma exhibit much higher response rates, ranging from 50% to 80%.[183.1] Furthermore, results from a phase 3 trial of immunotherapy with an anti-PD-1-based therapy demonstrated a continued long-term survival benefit in patients with advanced melanoma, with a median overall survival of 71.9 months (approximately 6 years) after a follow-up of at least 10 years.[185.1] This underscores the potential for long-term benefits of immunotherapy in certain malignancies.
In the context of non-small cell lung cancer (NSCLC), immunotherapy has been validated as beneficial for patients with brain metastases, with treatments showing superior efficacy compared to those who have not received immunotherapy.[186.1] The long-term survival benefits of immunotherapy are further supported by findings from large international studies, which indicate that immunotherapy can significantly improve long-term overall survival in advanced melanoma patients.[184.1]
Moreover, researchers have identified several key factors that influence the response to immunotherapy, including tumor mutational burden, T-cell infiltration, and previous treatment history. These factors can help tailor immunotherapy approaches to enhance patient outcomes and survival rates.[187.1] Overall, the advancements in immunotherapy represent a monumental breakthrough in cancer treatment, offering hope for improved survival and quality of life for many patients.
Immunotherapy has shown promising long-term benefits compared to traditional treatments for various cancers, particularly advanced non-small cell lung cancer (NSCLC) and melanoma. In a follow-up study of NSCLC patients treated with nivolumab, approximately 16% were still alive five years after treatment initiation, a significant improvement over the expected survival rate of 5% for similar patients in the US population.[188.1] This suggests that immunotherapy may provide substantial long-term survival advantages that traditional therapies may not achieve.
Moreover, large international studies have indicated that immunotherapy enhances overall survival rates in patients with advanced melanoma, reinforcing its potential as a more effective treatment option compared to conventional therapies.[189.1] The ability of immunotherapy to enable the immune system to recognize and destroy cancer cells marks a fundamental shift in cancer treatment paradigms, offering a mechanism that traditional treatments, such as chemotherapy and radiation, do not utilize.
Cost-effectiveness is a significant factor when evaluating immunotherapy in comparison to traditional treatments for non-small cell lung cancer (NSCLC). A major concern regarding immunotherapy is its high cost, with nivolumab costing approximately $24.69 per milligram, leading to an annual treatment expense that can reach up to $134,807.[191.1] However, immunotherapy can be a cost-effective option in several scenarios, particularly when strategies such as applying a discount on agents or utilizing PD-L1 expression as a biomarker are implemented to enhance its cost-effectiveness.[190.1] Notably, among the NSCLC studies reviewed, 21 out of 35 demonstrated that pembrolizumab, when used as a first-line treatment following PD-L1 assessment, was cost-effective at a threshold of $100,000 per quality-adjusted life year (QALY) compared to standard care.[192.1] These findings underscore the potential for immunotherapy to be economically viable under specific conditions, thereby improving access while maintaining sustainability in healthcare systems.[190.1]
A comprehensive management plan is essential for addressing the side effects associated with immunotherapy. Patients should be informed about potential side effects and develop a management strategy in collaboration with their cancer care team. This proactive approach can help patients feel more in control and alleviate anxiety related to treatment.[221.1]
Immunotherapy is a form of cancer treatment that utilizes the body's immune system to target and destroy cancer cells. While it is designed to enhance immune responses against cancer, immunotherapy can also lead to a range of side effects that differ from those associated with traditional chemotherapy.[223.1] Common side effects include fatigue, which may be attributed to changes in thyroid function, and immune-related (IR) colitis, characterized by inflammation of the large intestine, which manifests as diarrhea.[229.1] Additionally, the heightened activity of the immune system can inadvertently result in inflammation of healthy tissues, leading to various adverse effects.[224.1] Understanding these side effects is crucial for effective management and improving patient outcomes during immunotherapy treatment.[224.1]
To effectively manage these side effects, healthcare providers are encouraged to utilize established guidelines, such as those from the European Society for Medical Oncology (ESMO), which outline the grading and management of immune-related adverse events (irAEs).[225.1] These guidelines provide a framework for clinicians to identify and address the specific toxicities associated with immune checkpoint inhibitors and other immunotherapy modalities.
Immunotherapy can have significant psychological and emotional effects on patients undergoing treatment, including anxiety, depression, and mood swings.[230.1] A clearer understanding of the sources of anxiety for those undergoing immunotherapy is crucial, as anxiety during cancer treatment can lead to decreased treatment adherence and other negative outcomes.[231.1] Therefore, it is important for patients to be aware of these potential side effects and to seek support from their loved ones and healthcare professionals.[230.1] Understanding side effects encompasses not only clinical considerations but also emotional, social, and psychological aspects of patient care. This patient-centric approach enables healthcare providers to tailor treatments that best suit individual needs, ultimately improving overall well-being and treatment outcomes.[226.1]
Recent trends in ongoing studies of immunotherapy indicate a significant shift in the landscape of clinical trials. According to the Cancer Research Institute's 2023 update, there has been a notable decrease in the number of new immuno-oncology (IO) trials, marking the first decline since the analysis began in 2018. Specifically, there was a 2.86% decrease in new trials in 2022 compared to the previous year, primarily driven by a 6.4% reduction in phase 2 trials. Despite this decline, the number of investigational IO targets has reached a record high of 195, reflecting an expansion in the scope of IO-based therapies.[260.1]
In addition to the overall trends, specific breakthroughs in immunotherapy are being reported. For instance, a groundbreaking clinical trial demonstrated that an immune checkpoint inhibitor could lead to a complete clinical response in patients with locally advanced rectal cancer, effectively sparing them from chemoradiotherapy and surgery.[262.1] This highlights the potential of immunotherapy to transform treatment paradigms for certain cancer types.
Moreover, ongoing research is focusing on combination therapies that integrate immune checkpoint inhibitors (ICIs) with chimeric antigen receptor (CAR) T-cell therapy. This approach aims to enhance the immune response against tumors and improve clinical outcomes across various cancers.[263.1] The exploration of these innovative strategies is crucial, as they may address some of the limitations associated with traditional therapies.
However, the field of immunotherapy also faces significant challenges. Issues such as immunotherapy resistance, variability in patient responses, and the need for improved biomarkers hinder its widespread success.[291.1] A comprehensive analysis has identified nine major hurdles in advancing cancer immunotherapy, including limitations of current animal models, prolonged approval times for clinical trials, and the complexity of cancer itself.[292.1] Addressing these challenges is essential for translating the biological mechanisms of immunotherapy into effective clinical applications.
Emerging therapies in immunotherapy are increasingly focused on the identification and utilization of novel targets to enhance treatment efficacy. Mass spectrometry has been instrumental in the direct and unbiased discovery of tumor-specific human leukocyte antigen (HLA) peptides, which can be leveraged to define targets for immunotherapy. This approach facilitates the creation of a multi-target therapy warehouse, thereby accelerating clinical applications of these therapies.[265.1]
Recent studies have highlighted the significance of mutational burden in predicting patient responses to immunotherapy. For instance, a novel method developed by Roszik et al. utilizes a small next-generation sequencing (NGS) panel to predict total mutational load, demonstrating a strong correlation with outcomes in melanoma and non-small cell lung cancer (NSCLC).[266.1] This predictive capability is crucial for optimizing patient selection in clinical trials.
Moreover, the integration of immune checkpoint inhibitors, such as LAG3 and TIGIT blockade, is being explored to address emerging challenges like treatment resistance and adverse effects. These innovative combinations aim to enhance the overall efficacy of immunotherapy while identifying predictive biomarkers that can further refine patient selection.[267.1]
In the realm of surgical oncology, the role of immunotherapy is set to expand as new immune checkpoints are actively evaluated in clinical trials. These include lymphocyte activation gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3, which represent promising avenues for future therapeutic strategies.[269.1]
Patient-reported outcomes (PROs) are also gaining recognition in early clinical development, particularly for informing dose selection. Despite their potential benefits, PROs are infrequently included in the labeling of oncology drugs in the United States, although they are more prevalent in Europe and for non-oncology drugs.[268.1]
147
cancerprogressreport.aacr.org
188
news.cancerresearchuk.org
190
pubmed.ncbi.nlm.nih.gov
267
pubmed.ncbi.nlm.nih.gov